IXICO PLC — Regulatory Filings 2017

Mar 10, 2017

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 1369Z

IXICO plc

10 March 2017

10 March 2017

IXICO plc

("IXICO" or the "Company")

IXICO presents novel sleep measurement technology at a workshop on Mobile Devices for Clinical Trials in Neurological Diseases in Arizona, US.

IXICO, the brain health company, today announces that Professor Derek Hill will present IXICO's experimental technology to measure sleep from wearable sensors at a mobile devices for clinical trials in neurological diseases workshop involving global pharmaceutical companies.

IXICO's technology analyses data of sleep patterns obtained from wrist-worn accelerometers.  Its innovative algorithm was developed using the Artificial Intelligence "Deep Learning" technique utilising data from normal elderly patients as well as patients with neurodegenerative diseases wearing an accelerometer at a "gold standard" sleep-lab (polysomnography).

Sleep disturbance is a challenging symptom of many brain diseases.  It can also be a side effect of new drug treatments.  The ability to measure sleep accurately is therefore important for assessing both the benefits and side effects of new drugs under development for the treatment of serious diseases of the brain.

The mobile devices for clinical trials in neurological diseases workshop is jointly hosted by the Clinical Data Interchange Standards Consortium (CDISC) and the Critical Path Institute Coalition Against Major Diseases (CAMD), and is addressing the data standards challenges in enabling mobile devices to meet the rigorous regulatory requirements of the FDA.

Professor Derek Hill, Executive Director of IXICO, said: "We are pleased to showcase our innovative sleep measurement technologies at this prestigious workshop. Engaging with organizations such as CAMD and CDISC in advancing data standards and addressing regulatory challenges enables IXICO to provide our customers and collaboration partners in the pharmaceutical industry with unique solutions to meet their rapidly growing need for digital technologies to support the bringing of new drugs to market."

For further information please contact:

IXICO plc Giulio Cerroni, Chief Executive Officer Derek Hill, Executive Director Susan Lowther, Chief Financial Officer	Tel: +44 20 3763 7499
FTI Consulting Limited (Investor Relations) Simon Conway/Mo Noonan/Matthew Moss	Tel: +44 20 3727 1000

About IXICO

IXICO's innovative and proprietary digital healthcare technologies help those involved in researching and treating serious diseases to capture and analyse clinical data to make rapid, informed decisions.  In clinical research this includes the phenotyping of patients, quantification of disease pathology and measurement of patient outcomes.  In clinical practice the mobile health and digital decision support technologies aid diagnosis, patient engagement and monitoring. IXICO is also collaborating with partners to develop companion digital health products targeted at improving patient outcomes.

The Company's brain health focus includes Alzheimer's disease, Huntington's disease, multiple sclerosis, Parkinson's disease, behavioural health, child and adolescent mental health.

More information is available on www.ixico.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRALIFEAVFIILID